Jeffrey Rossi, MD
Internal Medicine · Cleveland, OHNPI 1689936809
Payments from drug & device makers
Across 316 payments — averaging $130.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$26K
- Inari Medical, Inc.$5K
- Abbott$4K
- Medtronic$2K
- Abiomed$1K
- Boston Scientific$1K
- plus $2K from 25 others
Across 1 payment — averaging $22.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$23
What the payments were for
- Consulting fees$18,58845%
- Speaking & faculty fees$4,25010%
- Travel & lodging$9,76924%
- Food & beverage$8,64921%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 57 | $26,156 |
| Inari Medical, Inc. | 31 | $4,913 |
| Abbott | 57 | $4,033 |
| Medtronic(2 entities) | 20 | $1,518 |
| Abiomed | 15 | $1,387 |
| Boston Scientific | 35 | $1,014 |
| Cardiovascular Systems Inc. | 39 | $365 |
| Shockwave Medical, Inc | 7 | $350 |
| Philips North America LLC | 7 | $288 |
| Biosense Webster, Inc. | 8 | $207 |
| Pfizer | 9 | $164 |
| Penumbra, Inc. | 2 | $159 |
| Heartflow, Inc. | 1 | $151 |
| AstraZeneca | 1 | $100 |
| Siemens Medical Solutions USA, Inc. | 1 | $89 |
| Zyla Life Sciences, Inc. | 3 | $62 |
| Stryker | 3 | $52 |
| Zimmer Biomet | 2 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $37 |
| Angiodynamics, Inc. | 2 | $35 |
| W. L. Gore & Associates, Inc. | 2 | $31 |
| Amgen | 2 | $31 |
| Cvrx, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Asahi Intecc USA, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $18 |
| Livanova USA, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Cordis US CORP. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$18,058
- CT THROMBECTOMY SYSTEM KIT$4,394
- FLOWTRIEVER CATHETER, S$4,394
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,962
- SAPIEN 3 Ultra RESILIA$1,539
- EVOQUE$1,113
- Impella$1,110
- Omnilink Elite vascular stent system$1,102
- CoreValve Evolut$1,055
- MitraClip$449
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$189
- FFRct$151
- Watchman$150
- Penumbra System$140
- GENERAL - STENTS$126
- AMPLATZER AMULET$103
How this compares
$41,355 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $216,169 |
| EntrestoSacubitril/Valsartan | 47 | $49,798 |
| BrilintaTicagrelor | 85 | $44,102 |
| Repatha SureclickEvolocumab | 31 | $37,041 |
| XareltoRivaroxaban | 24 | $23,425 |
| Praluent PenAlirocumab | 19 | $12,417 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $10,779 |
| Prasugrel Hcl | 64 | $8,854 |
| ClopidogrelClopidogrel Bisulfate | 819 | $7,779 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,998 |
| Ranolazine ErRanolazine | 17 | $2,538 |
| Metoprolol Succinate | 176 | $2,498 |
| Atorvastatin Calcium | 195 | $2,109 |
| Potassium Chloride | 110 | $1,977 |
| Amiodarone Hcl | 38 | $1,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $216,169193 claims |
| NovartisEntresto | $17 | $49,79847 claims |
| AstraZenecaBrilinta | $100 | $44,10285 claims |
| Johnson & JohnsonXarelto | $21 | $23,42524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cleveland
- Vadim KoshkinCleveland$6.1M
- Emily LittlejohnCleveland$885K
- Marina MagreyCleveland$856K
- Pushkar KanadeCleveland$753K
- Cyrus HarrisCleveland$726K
- Ila TamaskarCleveland$721K
- Amar KrishnaswamyCleveland$552K
- Albree Tower-RaderCleveland$522K
- Adriano TonelliCleveland$464K
- Mahboob RahmanCleveland$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.